Just looking at some of NEU's biotech peers (noting this a very simplistic back of the envelope comparison):
Mesoblast (MSB): MC $1.7 Billion, EV $1.5B (MC less $280M cash), 280M shares on issue, 9 products/target markets (stem cell?) in pipeline but all at Phase II i.e. still a few hoops to jump thru b4 commercialisation.
Prima Biomed (PRR): MC $184 Million, EV $180 (MC less $4M cash), 700M shares on issue, cell therapies targeting a number of cancers, at the Phase II stage.
NEU: MC $7 Million, EV $5M (MC less $2M cash), 500M shares, 2 products (one being the 'sexy' TBI market) nearing? Phase II completion.
What valuation NEU?, should they overcome Phase II hurdles?
NB - Prima Biomed and NEU have similar Springtree convertible note arrangements...
neu comparison vs other biotechs
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.35 |
Change
-0.510(2.57%) |
Mkt cap ! $2.494B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $5.988M | 307.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49 | $19.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.35 | 125 | 9 |
View Market Depth
| Last trade - 11.31am 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |